Search NLS News

Elicera Therapeutics has entered a research collaboration with Fourth Affiliated Hospital of China Medical University (CMU4). Through this agreement, the efficacy of the oncolytic virus ELC-201 will be evaluated in preclinical proof-of-concept studies across multiple solid tumor indications. “We are very pleased to have been able to establish yet another scientific collaboration to advance the development […]

HiloProbe has raised funding from existing owners. “The main focus of this capital injection is to initiate sales, enabling us to attract a larger amount of capital. We anticipate reaching a break-even point after that,” says Lina Olsson, CEO of HiloProbe. HiloProbe describes the interest in its product as “significant” and that the company is close […]

Data generated in the course of the collaboration have altered the risk-benefit profile within the intended indications. Merck will return all rights according to the licensing and collaboration agreement that was entered between the two parties in February 2023. Aqilion will ensure that all data and materials will be transferred to the company and will […]

His is not a household name, but the drugs developed thanks to Danish scientist Jens Juul Holst’s research certainly are.

Sound Bioventures has announced a new investment in NephroDI Therapeutics, a US-based, near-clinical stage pharmaceutical company focusing on concentration disorders of the kidney. In conjunction with this investment, Bibhash Mukhopadhyay, Managing Partner at Sound Bioventures, will join NephroDI’s Board of Directors. “At Sound Bioventures, we aim to back innovative companies working to address some of […]

HiloProbe has raised funding from existing owners. “The main focus of this capital injection is to initiate sales, enabling us to attract a larger amount of capital. We anticipate reaching a break-even point after that,” says Lina Olsson, CEO of HiloProbe. HiloProbe describes the interest in its product as “significant” and that the company is close […]

Celluminova has announced that the European Commission has granted Orphan Drug Designation for p-HTMI. Celluminova’s patented compound p-HTMI is the first molecule of its kind to enable detection of glioma stem cells by fluorescence during surgery for patients with malignant gliomas, including the most aggressive form called glioblastoma. By targeting these tumor-driving cells, p-HTMI may […]

In the old days, the major pharmaceutical companies and successful life science companies were generally in the driving seat and could pick and choose from qualified candidates. Prestigious public hospitals and/or hospitals located in the major city centers were in a similar position. Today the balance of power has  shifted somewhat, and because of the […]

Perpetua Medical has entered a letter of intent with the shareholders of ES-Medical regarding an investment in the company and acquisition of shares in ES-Medical. Perpetua Medical’s ownership is intended to amount to 70 percent of the shares in the company after the transaction, with an option to acquire the remaining 30 percent after three […]

The Board of Directors of Medfield Diagnostics has decided to apply to declare the company bankrupt. The bankruptcy application was filed June 18, 2024, with the Gothenburg District Court and it has approved the file for bankruptcy of Medfield Diagnostics. The reason for the bankruptcy filing is that, despite intensive work in 2024, Medfield has not […]